Table 4 Chi-square test analysis of the connection between AADAC expression and clinicopathological features
Characteristics | Low expression (n = 88) | High expression (n = 64) | p value |
|---|---|---|---|
Sex | Â | Â | 0.874 |
  Male | 65 (73.9) | 48 (75.0) |  |
  Female | 23 (26.1) | 16 (25.0) |  |
Age (years) | Â | Â | 0.027 |
  ≤60 | 39 (44.3) | 40 (62.5) |  |
  >60 | 49 (55.7) | 24 (37.5) |  |
BMI (kg/m2) | Â | Â | 0.787 |
  ≤24 | 69 (78.4) | 49 (76.6) |  |
  >24 | 19 (21.6) | 15 (23.4) |  |
Tumor diameter (mm) | Â | Â | 0.809 |
  ≤50 | 45 (51.1) | 34 (53.1) |  |
  >50 | 43 (48.9) | 30 (46.9) |  |
CEA | Â | Â | 0.499 |
  ≤5ng/ml | 72 (81.8) | 55 (85.9) |  |
  >5ng/ml | 16 (18.2) | 9 (14.1) |  |
CA19-9 | Â | Â | 0.885 |
  ≤37U/ml | 75 (85.2) | 54 (84.4) |  |
  >37U/ml | 13 (14.8) | 10 (15.6) |  |
Tumor location | Â | Â | 0.415 |
  Middle and Upper third | 22 (25.0) | 21 (32.8) |  |
  Lower third | 65 (73.9) | 43 (67.2) |  |
  Entire stomach | 1 (1.1) | 0 (0) |  |
Histological type | Â | Â | 0.583 |
  Well to moderately differentialed | 17 (19.3) | 12 (18.8) |  |
  Poor differentialed | 36 (40.9) | 31 (48.4) |  |
  Signet ring cell | 9 (10.2) | 3 (4.7) |  |
  Mucinous | 26 (29.6) | 18 (28.1) |  |
pTNM stage | Â | Â | 0.813 |
  I | 6 (6.8) | 5 (7.8) |  |
  II | 32 (36.4) | 26 (40.6) |  |
  III | 50 (56.8) | 33 (51.6) |  |
Vascular infiltration | Â | Â | 0.405 |
  Yes | 26 (29.5) | 23 (35.9) |  |
  No | 62 (70.5) | 41 (64.1) |  |
Nerve infiltration | Â | Â | 0.288 |
  Yes | 42 (47.7) | 25 (39.1) |  |
  No | 46 (52.3) | 39 (60.9) |  |
Postoperative chemotherapy | Â | Â | 0.038 |
  Yes | 28 (31.8) | 31 (48.4) |  |
  No | 60 (68.2) | 33 ( 51.6) |  |
HER2 expression | Â | Â | 0.403 |
  Negative or IHC 1+ | 68 (77.9) | 53 (82.8) |  |
  IHC 2+ or IHC 3+ | 20 (22.1) | 11 (17.2) |  |